Dexmedetomidine and Outcomes of Cardiac Surgery (DOCS)

• Status: Completed
• Trial end date: 2018-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Cardiac surgery is associated with a high risk of cardiovascular and other complications. The investigators hypothesized that perioperative infusion of dexmedetomidine may reduce the incidence of complications and mortality following cardiovascular surgery.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Xijing Hospital
• Treatments: Anesthetics; Dexmedetomidine

Criteria

Inclusion Criteria:

• Provide written informed consent

• Are > 18 years of age

• Elective cardiac surgery with CPB, when the surgeon plans to do valve and/or CABG surgery

Exclusion Criteria:

• Emergent cardiac surgery

• Other than CABG and/or Valve surgery

• off-pump or robotic surgery

• Surgery requiring deep hypothermic circulatory arrest or involving the thoracic aorta

• Life expectancy < 1 year

• Preop severe liver or renal dysfunction, with replacement therapy required

• Patients with IABP or with cardiogenic shock

• Severe dehydrate or dystrophia or Hb < 10 g/dl

• History of any alpha-2 receptor agonists allergy.

• Refuse to provide written informed consent

• Diagnosed with mental illness